Engineered cytokine products represent a growing class of therapeutic proteins which need to be tested for biological activity at various stages of pharmaceutical development. In most cases, dedicated biological assays are established for different products, in a process that can be time-consuming and cumbersome. Here we describe the development and implementation of a universal cell-based reporter system for various classes of immunomodulatory proteins. The novel system capitalizes on the fact that the signaling of various types of pro-inflammatory agents (e.g., cytokines, chemokines, Toll-like receptor agonists) may involve transcriptional activation by NF-kB. Using viral transduction, we generated stably-transformed cell lines of B or T lymphocyte origin and compared the new reporter cell lines with conventional bioassays. The experimental findings with various interleukins and with members of the TNF superfamily revealed that the newly-developed "universal" bioassay method yielded bioactivity data which were comparable to the ones obtained with dedicated conventional methods. The engineered cell lines with reporters for NF-kB were tested with several antibody-cytokine fusions and may be generally useful for the characterization of novel immunomodulatory products. The newly developed methodology also revealed a mechanism for cytokine potentiation, based on the antibody-mediated clustering of TNF superfamily members on tumor-associated extracellular matrix components.
INTRODUCTION
The clinical success of immune check-point inhibitors for the treatment of various forms of cancer [1] [2] [3] has sparked research activities for the discovery and development of novel immunostimulatory products. Various types of engineered cytokine products (e.g., antibodycytokine fusion proteins [4] [5] [6] and polymer-cytokine conjugates 7, 8 , chemokines 9 and Toll-like receptor agonists 10 have been considered for cancer therapy applications.
The development of novel immunostimulatory products requires the implementation of reliable quantitative methods for the determination of biological activity. Such methods are important both at the research stage and during industrial production, since a demonstration of consistent biological activity throughout the development process is a prerequisite for quality assurance and for enabling comparisons of experimental results.
At present, dedicated assays are established for individual products but most methodologies are not readily applicable to different types of biopharmaceuticals 11 . For example, interleukin-2 (IL2) activity is typically measured by the ability to induce proliferation of the CTLL-2 cell line of T cell origin 12 , while Interleukin-12 (IL12) activity tests measure the production of interferon-g by NK-92 cells of NK cell origin 13, 14 . The activity of tumor necrosis factor (TNF) and of TNF-based biopharmaceuticals is often measured by the killing of transformed fibroblast cell lines 15 , while other members of the TNF superfamily are studied in terms of their ability to stimulate the production of pro-inflammatory cytokines by splenocytes 16, 17 or the proliferation of splenic subsets 18, 19 .
The development of dedicated methods for individual products is often cumbersome and may require the generation of stably transfected cell lines 20 . Moreover, the optimization of technical parameters, such as cell growth conditions and dose-response relationships, may be time-consuming. Our laboratory has worked on the development and characterization of more than 100 different antibody-cytokine and antibody-chemokine fusions proteins 4, 21 and has learned to value the importance of robust, reliable and broadly applicable methodologies for the study of engineered cytokine products.
Here we report on the development of two general reporter cell lines, which are derived from T and B lymphocytes and which are broadly applicable for the quantification of biological activity of immunostimulatory agents. We used viral transduction methodologies with a reporter for NF-kB activity because of the central role played by NF-kB signaling in many different inflammatory processes 22 .
The term NF-kB refers to a variety of homo-and heterodimers that are formed between members of the NF-kB family of proteins. The members of the NF-kB family of proteins all share a related REL homology domain (RHD), which confers both DNA binding and dimerization. Activated NF-kB dimers localize to the nucleus where they bind to the NF-kB response element that has the loose consensus sequence 5ʹ-GGRNN(WYYCC)-3ʹ (where R: purine, N: any base, W: adenine or thymine and Y: pyrimidine) [23] [24] [25] and thus activates the transcription of a variety of target genes (via interaction with basal transcription factors and cofactors). In the absence of signaling, the NF-kB proteins are present in the cell as preformed complexes that can be rapidly activated upon signaling 24, 25 . The signaling complexes can either be activated by degradation of an inhibitory protein or by the removal of an inhibitory protein domain by upstream signaling components 26 .
Even though class I cytokines typically signal via JAK/STAT activation 27 , there is evidence that most of them directly or indirectly also trigger the activation of NF-kB [28] [29] [30] [31] . By contrast, members of the TNF superfamily of proteins signal via the recruitment of TNF Receptor Associated Factors (TRAF) that activate NF-kB both via the classical and the non-canonical pathway [32] [33] [34] .
The newly developed cell lines (termed CTLL-2_NF-kB and A20_NF-kB) were used to implement a general bioassay, which was compared to established procedures for the characterization of various types of engineered cytokine products. Moreover, the new methodologies allowed the discovery of a novel strategy for cytokine potentiation, based on the antibody-mediated clustering of multimeric immunostimulatory payloads (e.g., members of the TNF superfamily) on tumor-associated extracellular matrix components.
MATERIALS AND METHODS

Cell lines
The murine cytotoxic T cell line CTLL-2 (ATCC® TIB-214), the murine B lymphocyte cell line A20 (ATCC® TIB-208) and the murine fibroblast cell line LM (ATCC® CCL-1.2) and were obtained from ATCC, expanded and stored as cryopreserved aliquots in liquid nitrogen. The CTLL-2 cells were grown in RPMI 1640 (Gibco, #21875034) supplemented with 10% FBS (Gibco, #10270106), 1 X antibiotic-antimycoticum (Gibco, #15240062), 2 mM Ultraglutamine (Lonza, #BE17-605E/U1), 25 mM HEPES (Gibco, #15630080), 50 µM b-mercaptoethanol (Sigma Aldrich) and 60 U/mL human IL-2 (Proleukin, Roche Diagnostics). The A20 cells were grown in RPMI 1640 (Gibco, #21875034) supplemented with 10% FBS (Gibco, #10270106), 1 X antibiotic-antimycoticum (Gibco, # 15240062) and 50 µM b-mercaptoethanol (Sigma Aldrich).
The L-M fibroblasts were grown in DMEM (Gibco, high glucose, pyruvate, #41966-029) supplemented with 10% FBS (Gibco, #10270106) and 1 X antibiotic-antimycoticum (Gibco, #15240062). The cells were passaged at the recommended ratios and never kept in culture for more than one month. The NK-92 cells were obtained from DSMZ (ACC 488) and grown in in MEM Alpha medium (Gibco, #22571-020) supplemented with 5 ng/mL recombinant human Proteins were produced by transient transfection of CHO-S cells and purified by protein A affinity chromatography as described previously [35] [36] [37] . Quality control of the purified products included SDS-PAGE, size exclusion chromatography and, where applicable, mass spectrometry [ Supplementary Figure 3 ].
Virus production and stable transduction
For the virus production, 5 million HEK293T cells were seeded at a density of 300'000 cells/mL on the day prior to transfection. They were then transiently co-transfected with the reporter plasmid pJM046 as well as the packaging plasmid psPAX2 and the envelope plasmid pCAG-VSVG using the jetPRIME reagent (Polyplus transfection). The packaging and the envelope plasmid were kindly provided by the group of Prof.Markus Manz. The medium was replaced on the day after the transfection and the virus was harvested on the following day. The virus was aliquoted and snap-frozen in an ethanol dry ice mixture. An aliquot was thawed and used for the transduction of 500'000 target cells. After transduction the cells were expanded, activated and mCherry-positive cells were sorted by FACS (BD FACS AriaIII).
CTLL-2 proliferation assay
CTLL-2 cells were washed twice with prewarmed HBSS (Gibco, #14175095) and then grown in the absence of IL-2 for 24 h in RPMI1640 (Gibco, # 21875034) medium supplemented with 10% FBS (Gibco, #10270106), 1 X antibiotic-antimycoticum (Gibco, # 15240062), 2 mM Ultraglutamine (Lonza, # BE17-605E/U1), 25 mM HEPES (Gibco, # 15630080) and 50 µM bmercaptoethanol (Sigma Aldrich). The starved CTLL-2 cells were seeded in a 96-well plate (20'000 cells/well) and medium supplemented with varying concentrations of IL-2 was added.
All dilutions were done in triplicates. After 48 h incubation at 37°C, 5% CO2 CellTiter 96
Aqueous One Solution (Promega, #G3582) was added to measure cell proliferation.
Absorbance at 490 nm and 620 nm was measured after 1.5 h. The relative proliferation was calculated using the formula: relative proliferation = (OD490-620 treated -OD490-620 medium )/ (OD490-620 untreated -OD490-620 medium ) x 100%. The data was fitted using the [Agonist] vs. response (three parameters) fit of the GraphPad Prism 7.0 a software to estimate the EC50.
IL-12 assay
The method was adapted from previous publications 14, 38 . Briefly, NK92 cells were seeded at a density of 100'000 cells per well in a 96-well plate and 100 µL of medium containing varying concentrations of L19-IL12 was added. After 24 h of incubation at 37°C, 5% CO2, the concentration of IFN-g in the cell culture supernatant was determined by ELISA (Invitrogen, #EHIFNG2). The data was fitted using the [Agonist] vs. response (three parameters) fit of the GraphPad Prism 7.0 a software to estimate the EC50.
TNF assay L-M fibroblasts were seeded at a density of 20'000 cells/well in a 96-well plate and incubated for 24 h at 37°C, 5% CO2. The medium was replaced by 100 µL fresh medium containing 2 µg/mL Actinomycin D (BioChemica, #A1489,0005) and varying concentrations of F8-TNF. The cells were incubated at 37°C, 5% CO2 for another 24 h before 20 µL of CellTiter 96 Aqueous One Solution (Promega, #G3582) was added and absorbance at 490 nm and 620 nm was measured. The % cell survival was calculated using the formula: relative proliferation = (OD490-620 treated -OD490-620 medium )/ (OD490-620 untreated -OD490-620 medium ) x 100%. The data was fitted using the [Agonist] vs. response (three parameters) fit of the GraphPad Prism 7.0 a software to estimate the EC50.
NF-kB response assay
CTLL-2 reporter cells were starved for 6 -9 h as described above prior to use in order to reduce the background signal. If necessary, 100 µL 100 nM 11-A-12 fibronectin in phosphate buffered saline (PBS) was added to each well to be coated with EDA and the plate was incubated at 37°C for 90 min. Cells were seeded in 96-well plates (50'000 cells/well) and growth medium containing varying concentrations of the cytokine to be tested was added. The cells were incubated at 37°C, 5% CO2 for several hours. To assess luciferase production, 20 µL of the supernatant was transferred to an opaque 96-well plate (PerkinElmer, Optiplate-96, white, Figure 1 describes the strategy followed for the generation of a universal reporter system for cytokine activity. The signaling of many different pro-inflammatory mediators (e.g., chemokines, Toll-like receptor agonists, members of the TNF superfamily and various other cytokines) involves the activation of NF-kB, in addition to other signaling pathways [ Figure   1a ] 23, 30, 39, 40 . We constructed a vector for virus-mediated stable cell transduction, which incorporated an NF-kB response element upstream of a secreted luciferase (NanoLuc) and mCherry reporter genes [Supplementary Figure 1 We investigated the possibility of using the newly developed transduction method as a universal reporter for cytokine activity by performing a comparison with established dedicated test systems. For this experiment, antibody-cytokine fusions that have previously been developed in our lab were used [35] [36] [37] . We used fusions of the L19 antibody targeting the extradomain B of fibronectin 41 linked to human IL2 and murine IL12, as well as fusions of the F8 antibody targeting the extradomain A of fibronectin 42 linked to murine tumor necrosis factor (TNF) [Figure 2 ]. Interleukin-2 (IL2) activity was measured both in terms of proliferation of non-transduced CTLL-2 cells and in terms of NF-kB reporter activity in transduced cells. An EC50 value in the 10 pM range was observed for both methodologies [Figure 2a] [ Supplementary Table T1 ]. The activity of interleukin-12 (IL12) is often measured in terms of interferon-g production by NK-92 cells of Natural Killer cell origin 14 . In this case, the EC50 values obtained using the NK-92 cell-based system were roughly ten times lower than those obtained by monitoring NF-kB reporter activity [Figure 2b and Supplementary Table T1 ]. The performance of the new methodology for the measurement of TNF activity was compared to the results of a conventional cell killing assay, using a transformed fibroblast cell line which is particularly sensitive to the action of TNF. EC50 values in the pM range were observed for the killing assay, whereas the EC50 values obtained with the universal assay were in the 100 pM range [ Figure 2C and Supplementary Table T1 ].
RESULTS AND DISCUSSION
We then used the of NF-kB reporter assay for the characterization of three novel fusion proteins, featuring the F8 antibody (specific to the alternatively-spliced EDA domain of fibronectin, a tumor-associated antigen) 42 fused to three different members of the TNF superfamily [ Figure 3 ]. Our lab has had a long-standing interest in the characterization of the tumor-homing properties 43 and anti-cancer activity of antibody fusion proteins with members of the TNF superfamily 36, 44 . F8-41BBL, F8-GITRL and F8-CD154 featured the TNF superfamily member as single-chain polypeptide in order to stabilize the homotrimeric structure 20 while the antibodies were used as recombinant diabody moieties 45 . A concentration-dependent NF-kB reporter activity could be measured for all three antibodycytokine fusions, monitoring both luciferase activity and mCherry expression [Figure 3 ]. The EC50 values obtained for 4-1BBL and GITRL constructs were in the nanomolar range whereas the values obtained for the CD154 construct were in the 100 pM range [ Supplementary Table   T2 ].
Antibody-cytokine fusions are increasingly being used for the therapy of cancer 5,6,21 and of chronic inflammatory conditions 46, 47 with the aim to concentrate cytokine activity at the site of disease and help spare normal organs. We used derivatives of the F8 antibody to assess whether a localized concentration of cytokine activity in close proximity to target cells of interest may lead to a potentiation of biological activity. The alternatively-spliced EDA domain of fibronectin (i.e., the target antigen of the F8 antibody) is typically found as an abundant component of the modified extracellular matrix associated with newly-formed tumor blood vessels 48 , but is otherwise undetectable in most normal adult tissues, exception made for the female reproductive system 49 . We mimicked the localized deposition of EDA(+)-fibronectin by coating plastic wells with 11-A-12 recombinant fibronectin fragments, containing the EDA domain 42 [Figure 4a] . The system was used to compare the biological activity of F8-41BBL, F8-GITRL and F8-CD154 fusion proteins, featuring the F8 antibody either in diabody format linked to a single-chain trimer of the cytokine or as single-chain Fv fragment linked to a single unit of the cytokine [Figure 4b-d ]. In the case of the F8 antibody in a diabody format linked to a single-chain trimeric 4-1BBL, only a small increase in stimulatory activity was observed when the agonist was clustered on EDA. However, in the case of the single-chain Fv fragment linked to a single 4-1BBL unit, no activity was observed in the absence of clustering. Activity could in this case be restored by clustering the agonist on EDA coated wells [Figure 4b ].
The observation that the activity of murine 4-1BBL can be potentiated by clustering of antibody fusions on specific tumor-associated extracellular matrix components is surprising and potentially useful for pharmaceutical applications. Murine 4-1BBL is not able to form stable homotrimers, but rather forms low-activity homodimeric structures 50, 51 . It is possible that the high-density binding of F8 fusions on EDA-containing fibronectin promotes the formation of supermolecular assemblies, which gain signaling activity in a concentrationdependent manner [Figure 4b ]. This approach mimics on the extracellular matrix what happens on murine cells where surface display of multiple copies of dimeric ligands turns an inactive homodimer into an active multimeric assembly 50, 51 . Some potentiation upon antigen binding had previously been reported for certain murine TNF fusions 52 and for other members of the TNF superfamily 53, 54 . In principle, it would be attractive to engineer antibody-cytokine fusions which gain activity at the site of disease (e.g., upon antigen binding) while sparing normal tissues, as this approach could lead to biopharmaceuticals with improved therapeutic index. Our group has recently described a conceptually similar strategy, based on the assembly of heterodimeric split cytokine fusions (e.g., interleukin-12 superfamily members) 55 .
Other strategies for the conditional potentiation of antibody-cytokine include the allosteric regulation of cytokine activity 56 or the attenuation of cytokine potency ("attenukine") 57 .
Strategies aimed at potentiating the activity of antibody therapeutics based on conditional oligomerization include the development of hexameric IgG antibodies to augment complement-mediated cytotoxicity 58, 59 .
In this article we have mainly focused on recombinant and engineered cytokine products.
While many interleukins mainly signal through JAK/STAT activation 27 , NF-kB-driven transcriptional events are also induced, in line with previous reports on this matter [28] [29] [30] [31] . NF-kB reporters should be broadly applicable also to other classes of pro-inflammatory products.
Both Toll-like receptors and members of the interleukin-1 receptor superfamily activate NF-kB through the recruitment of MyD88 as part of their signal transduction 39 . In addition, there is also evidence that NF-kB can be activated by chemokine signaling 40 .
The CTLL-2 and A20 cell lines express on their surface a large variety of receptors of immunological importance and should be therefore applicable for many different bioactivity assays. If a researcher is interested in the use of a different cell line, the viral transduction system described in Figure 1 should enable the rapid preparation of the corresponding reporter system. The intracellular expression of mCherry was found to be useful for sorting of positively transduced cells by flow cytometry, while the secreted luciferase rapid a facile readout of the reporter activity.
In summary, we have generated new universal reporter systems for the facile measurement of biological activity of various types of pro-inflammatory mediators and engineered cytokine products. We anticipate that the newly-developed cell lines and vector may find a broad applicability in biological, pharmaceutical and immunological research. activity of single-chain trimeric CD154 fused to the F8 antibody in the single-chain diabody format using the A20 reporter cell line. In the cases where a strong hook effect was observed, only the sigmoidal part was used for curve fitting as indicated by the solid line. 
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